Neonatal Intensive Care Unit, Mount Sinai Hospital, Toronto, ON, Canada.
Drugs R D. 2011 Sep 1;11(3):215-26. doi: 10.2165/11593140-000000000-00000.
Respiratory syncytial virus (RSV) is a highly contagious virus, and is the major cause of lower respiratory tract infections in infants and toddlers worldwide. RSV infection poses serious health risks to young children during the first 2 years of life. Several infant populations have been classified as high risk, and additional risk factors are known to increase the likelihood of severe RSV infection. Treatment for active RSV infection is limited to the symptoms of infection rather than the underlying cause; therefore, it is critical to reduce the transmission of RSV. As nurses, we highlight the importance of educating healthcare professionals, both in the hospital and community settings, as well as parents and other caregivers about the risks and outcomes associated with RSV infection, and necessary measures to decrease the risk of infection. We also highlight the importance of the successful identification of those children who are at high risk of RSV infection. RSV prophylaxis (RSVP) with palivizumab has been shown to improve clinical outcome in infants who are considered high risk compared with those who have not received RSVP. The failure of healthcare staff and primary caregivers to protect children against an RSV infection can have lasting detrimental effects on the health and lives of affected children and their families.
呼吸道合胞病毒(RSV)是一种高度传染性病毒,是全球婴儿和幼儿下呼吸道感染的主要原因。RSV 感染对生命最初 2 年的幼儿构成严重健康风险。有几个婴儿群体被归类为高风险,并且已知其他风险因素会增加严重 RSV 感染的可能性。针对 RSV 感染的治疗仅限于感染的症状,而不是根本原因;因此,减少 RSV 的传播至关重要。作为护士,我们强调了向医院和社区环境中的医疗保健专业人员、父母和其他照顾者教育 RSV 感染相关风险和结果以及减少感染风险的必要措施的重要性。我们还强调了成功识别那些有 RSV 感染高风险的儿童的重要性。与未接受 RSV 预防接种的婴儿相比,使用帕利珠单抗进行 RSV 预防接种(RSVP)已被证明可改善高危婴儿的临床结局。医疗保健人员和主要照顾者未能保护儿童免受 RSV 感染会对受感染儿童及其家庭的健康和生活产生持久的不利影响。